Barclays PLC Has $329,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS)

Barclays PLC raised its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 361.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,308 shares of the biopharmaceutical company’s stock after purchasing an additional 30,792 shares during the quarter. Barclays PLC owned 0.07% of Emergent BioSolutions worth $329,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of EBS. Meeder Asset Management Inc. acquired a new position in Emergent BioSolutions during the second quarter valued at $41,000. Stifel Financial Corp purchased a new position in Emergent BioSolutions during the 3rd quarter valued at about $96,000. FORA Capital LLC acquired a new position in shares of Emergent BioSolutions in the 3rd quarter valued at about $103,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Emergent BioSolutions in the second quarter worth approximately $93,000. Finally, Morse Asset Management Inc acquired a new stake in shares of Emergent BioSolutions during the second quarter worth approximately $97,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on EBS. Benchmark upped their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Rodman & Renshaw reiterated a “buy” rating and set a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th. HC Wainwright initiated coverage on Emergent BioSolutions in a research report on Monday, December 30th. They set a “buy” rating and a $15.00 price objective for the company. Finally, StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Saturday, December 28th.

Emergent BioSolutions Trading Up 0.5 %

Shares of NYSE:EBS opened at $10.32 on Friday. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The stock has a market capitalization of $559.18 million, a PE ratio of -2.52 and a beta of 1.60. Emergent BioSolutions Inc. has a 1 year low of $1.42 and a 1 year high of $15.10. The firm has a fifty day moving average price of $9.27 and a 200 day moving average price of $8.98.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.